These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 12871065)

  • 1. Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor.
    Ploug M
    Curr Pharm Des; 2003; 9(19):1499-528. PubMed ID: 12871065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural analysis of the interaction between urokinase-type plasminogen activator and its receptor: a potential target for anti-invasive cancer therapy.
    Ploug M; Gårdsvoll H; Jørgensen TJ; Lønborg Hansen L; Danø K
    Biochem Soc Trans; 2002 Apr; 30(2):177-83. PubMed ID: 12023847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
    Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
    Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding.
    Quax PH; Grimbergen JM; Lansink M; Bakker AH; Blatter MC; Belin D; van Hinsbergh VW; Verheijen JH
    Arterioscler Thromb Vasc Biol; 1998 May; 18(5):693-701. PubMed ID: 9598826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A competitive chromogenic assay to study the functional interaction of urokinase-type plasminogen activator with its receptor.
    Rettenberger P; Wilhelm O; Oi H; Weidle UH; Goretzki L; Koppitz M; Lottspeich F; König B; Pessara U; Kramer MD
    Biol Chem Hoppe Seyler; 1995 Oct; 376(10):587-94. PubMed ID: 8590627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site.
    Ploug M
    Biochemistry; 1998 Nov; 37(47):16494-505. PubMed ID: 9843416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
    Plesner T; Behrendt N; Ploug M
    Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ligand binding regions in the receptor for urokinase-type plasminogen activator.
    Liang OD; Chavakis T; Kanse SM; Preissner KT
    J Biol Chem; 2001 Aug; 276(31):28946-53. PubMed ID: 11501527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycosylation profile of a recombinant urokinase-type plasminogen activator receptor expressed in Chinese hamster ovary cells.
    Ploug M; Rahbek-Nielsen H; Nielsen PF; Roepstorff P; Dano K
    J Biol Chem; 1998 May; 273(22):13933-43. PubMed ID: 9593742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane. Evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction.
    Ploug M; Rahbek-Nielsen H; Ellis V; Roepstorff P; Danø K
    Biochemistry; 1995 Oct; 34(39):12524-34. PubMed ID: 7548000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis of interaction between urokinase-type plasminogen activator and its receptor.
    Barinka C; Parry G; Callahan J; Shaw DE; Kuo A; Bdeir K; Cines DB; Mazar A; Lubkowski J
    J Mol Biol; 2006 Oct; 363(2):482-95. PubMed ID: 16979660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential binding of urokinase and peptide antagonists to the urokinase receptor: evidence from characterization of the receptor in four primate species.
    Engelholm LH; Behrendt N
    Biol Chem; 2001 Mar; 382(3):435-42. PubMed ID: 11347891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional analysis of the cellular receptor for urokinase in plasminogen activation. Receptor binding has no influence on the zymogenic nature of pro-urokinase.
    Ellis V
    J Biol Chem; 1996 Jun; 271(25):14779-84. PubMed ID: 8662951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics.
    Schmiedeberg N; Schmitt M; Rölz C; Truffault V; Sukopp M; Bürgle M; Wilhelm OG; Schmalix W; Magdolen V; Kessler H
    J Med Chem; 2002 Nov; 45(23):4984-94. PubMed ID: 12408709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation.
    Ploug M; Ostergaard S; Hansen LB; Holm A; Danø K
    Biochemistry; 1998 Mar; 37(11):3612-22. PubMed ID: 9521680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.
    Yin S; Lockett J; Meng Y; Biliran H; Blouse GE; Li X; Reddy N; Zhao Z; Lin X; Anagli J; Cher ML; Sheng S
    Cancer Res; 2006 Apr; 66(8):4173-81. PubMed ID: 16618739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor.
    Ploug M; Ellis V; Danø K
    Biochemistry; 1994 Aug; 33(30):8991-7. PubMed ID: 8043585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator.
    Magdolen V; Rettenberger P; Koppitz M; Goretzki L; Kessler H; Weidle UH; König B; Graeff H; Schmitt M; Wilhelm O
    Eur J Biochem; 1996 May; 237(3):743-51. PubMed ID: 8647121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
    Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
    Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis.
    Zhou HM; Nichols A; Meda P; Vassalli JD
    EMBO J; 2000 Sep; 19(17):4817-26. PubMed ID: 10970872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.